AACR 2017: Interim Results of Phase Ib/II Trial of Neratinib in Combination With Ado-trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Key Points

  • For the 16 patients who were evaluable for efficacy, the objective response rate was 56%.
  • Efficacy results demonstrated that 3 patients had a complete response  lasting 17.1 months, 11.9 months, and 12+ months; 6 patients had a partial response; 3 patients had stable disease; and 4 patients had progressive disease.
  • The most frequently observed grade 3 adverse events were diarrhea, nausea, thrombocytopenia, and hypertension.

Interim results from the phase Ib/II FB-10 clinical trial of neratinib given in combination with the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1, Kadcyla) were reported in a poster at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, according to an announcement from Puma Biotechnology, Inc.

The trial enrolled patients with HER2-positive metastatic breast cancer who had previously been treated with chemotherapy and the combination of trastuzumab (Herceptin) and pertuzumab (Perjeta). Study treatment consisted of the standard dose of ado-trastuzumab emtansine at 3.6 mg/kg administered intravenously every 3 weeks and neratinib administered orally at escalating doses of 120, 160, 20, and 240 mg/d continuously. Primary diarrhea prophylaxis with high-dose loperamide was administered.

For the 16 patients who were evaluable for efficacy, the objective response rate (complete plus partial responses) was 56%. More specifically, the efficacy results from the trial demonstrated that 3 patients had a complete response (CR) lasting 17.1 months, 11.9 months, and 12+ months; 6 patients had a partial response (PR); 3 patients had stable disease (SD); and 4 patients had progressive disease (PD).

The number and types of response per dose cohort are summarized in the table below:


 Neratinib Dose 

 Number of Objective Responses (Number of  Evaluable Responses)

 120 mg/d

 5 CR/5 PR (2 CR, 3 PR)

 160 mg/d

 2 CR/4 PR (1 CR, 1 PR, 2 PD)

 200 mg/d

 1 CR/5 PR (1 PR, 2 SD, 2 PD)

 240 mg/d

 1 CR/2 PR (1 PR, 1 SD)

 

The most frequently observed grade 3 adverse events were diarrhea, nausea, thrombocytopenia, and hypertension. More specifically, for the 21 patients with available safety assessments, grade 3 diarrhea was reported in 4 patients (19%), grade 3 nausea was reported in 3 patients (14%), grade 3 thrombocytopenia was reported in 3 patients (14%), and grade 3 hypertension was reported in 2 patients (10%). There was 1 dose-limiting toxicity at the 120-mg dose (1 of 6 patients), 3 dose-limiting toxicities at the 200-mg dose (3 of 8), and 2 dose-limiting toxicities at the 240-mg dose (2 of 3). Additional patients are currently being accrued at the 160-mg dose in order to define the recommended phase II dose.

Jame Abraham, MD, FACP, Director of the Breast Oncology Program at Taussig Cancer Institute, Professor of Medicine at Cleveland Clinic, and principal investigator of the study, said, “We are encouraged by these initial findings and we will continue to enroll patients at the 160 mg dose to further evaluate the impact in this patient population.”

Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, “We are pleased to see the high response rate of the combination of T-DM1 and neratinib in this patient population who were previously treated with both pertuzumab and trastuzumab in this study. We look forward to completing enrollment in the current cohort and moving this combination into phase II trials.”

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement